Capital News

Opioid Related Disorder Pipeline Analysis: 10+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Opioid Related Disorder Pipeline Analysis: 10+ Companies are Working to Improve the Treatment Space | DelveInsight

December 07
05:10 2022
Opioid Related Disorder Pipeline Analysis: 10+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Opioid Related Disorder Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Opioid Related Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Opioid Related Disorder Pipeline Insight Report

  • DelveInsight’s Opioid Related Disorder Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Opioid Related Disorder.
  • The leading Opioid Related Disorder Companies are working such as GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others.
  • Promising Opioid Related Disorder Pipeline Therapies such as RBP-6000, Generic H/A taken first, RBP-6300, buprenorphine hydrochloride, Buprenorphine soluble film, telaprevir, oxycodone and naltrexone, Drug: Heroin, Drug: Naloxone, Drug: Lofexidine, and others.
  • The Opioid Related Disorder Companies and academics are working to assess challenges and seek opportunities that could influence Opioid Related Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Related Disorder.

 

Recent Developmental Activities in the Opioid Related Disorder Pipeline

  • Astellas Pharma’s lead drug candidate, ASP8062, is an analgesic class drug. It is an orally active γ-amino-butyric acid type B (GABAB) receptor positive allosteric modulator currently in phase II development. Phase 2 data demonstrated that ASP8062 for the treatment of Opioid Related Disorder as well as pain has beneficial effects. It was safe and well tolerated by the healthy subjects. It enhances the GABAergic transmission mediated by GABAB receptors by increasing the potency of endogenous agonist without overstimulating the receptor.
  • Opiant Pharmaceuticals “breakthrough” drug OPNT-003 is a long lasting opioid antagonist for the treatment of Opioid overdose and has demonstrated positive data from its phase I trials.

 

Get an overview of the Opioid Related Disorder Pipeline landscape @ Opioid Related Disorder Pipeline Outlook Report

 

Opioid Related Disorder Overview

Opioids are a class of drugs that bind with the opioid receptor present on the central nervous system in the brain and body to reduce the sensation of pain. Opioids predominantly include prescription pain relievers, synthetic opioids, and heroines. Although opioids reduce the perception of pain but chronic use of opioids can cause distress and impairment. Opioid Related Disorder includes overpowering desire to use opioids, dependence, increased opioid tolerance, and addictions which represents the most severe form of the disorders. When discontinued, the individual suffers from withdrawal syndrome.

 

Opioid Related Disorder Treatment

An effective treatment for Opioid Related Disorder generally includes pharmacotherapy. Three FDA approved medications present for the treatment of individuals with Opioid Related Disorder are naltrexone, methadone, and buprenorphine. These medications are more successful than other treatments for improving retention in addiction treatment. Opioid Related Disorder is diagnosed by clinicians by taking history, evaluating symptoms, using clinical information to identify a problematic pattern of opioid related impairment and distress as well as using 11 diagnostic criteria mentioned in Diagnostic and Statistical Manual of Mental Disorders, fifth edition.

 

Opioid Related Disorder Emerging Drugs Profile

  • ASP8062: Astellas Pharma
  • OPNT-003 (Intranasal Nalmefene): Opiant Pharmaceuticals

 

Opioid Related Disorder Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Opioid Related Disorder. The companies which have their Opioid Related Disorder drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Astellas Pharma and others.

 

Request a sample and discover the recent advances in Opioid Related Disorder Treatment Drugs @ Opioid Related Disorder Ongoing Clinical Trials Analysis

 

Opioid Related Disorder Therapeutics Assessment

The Opioid Related Disorder pipeline report proffers an integral view of the Opioid Related Disorder emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Opioid Related Disorder Pipeline Report

  • Coverage- Global
  • Opioid Related Disorder Companies are working such as GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others.
  • Opioid Related Disorder Pipeline Therapies such as RBP-6000, Generic H/A taken first, RBP-6300, buprenorphine hydrochloride, Buprenorphine soluble film, telaprevir, oxycodone and naltrexone, Drug: Heroin, Drug: Naloxone, Drug: Lofexidine, and others.

 

Table of Content

  1. Introduction
  2. Opioid Related Disorder Executive Summary
  3. Opioid Related Disorder: Overview
  4. Opioid Related Disorder Pipeline Therapeutics
  5. Opioid Related Disorder Therapeutic Assessment
  6. Opioid Related Disorder – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Opioid Related Disorder Collaboration Deals
  9. Mid Stage Products (Phase II)
  10. ASP8062: Astellas Pharma
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. OPNT-003: Opiant Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Opioid Related Disorder Key Companies
  19. Opioid Related Disorder Key Products
  20. Opioid Related Disorder- Unmet Needs
  21. Opioid Related Disorder- Market Drivers and Barriers
  22. Opioid Related Disorder- Future Perspectives and Conclusion
  23. Opioid Related Disorder Analyst Views
  24. Opioid Related Disorder Key Companies
  25. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Opioid Related Disorder drugs?
  • How many Opioid Related Disorder drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Related Disorder?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Opioid Related Disorder therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Opioid Related Disorder and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Opioid Related Disorder Pipeline therapeutics, reach out to Opioid Related Disorder Treatment Landscape

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/